Venous thromboembolism (VTE) afflicts persons across all age groups with a broad range
of characteristics, varying from previously healthy to multimorbid, polymedicated
patients [
[1]
]. To assess potential heterogenous treatment effects in specific subgroups of participants
or consistency of effects across different subgroups (such as women and men, those
with or without certain co-morbidities, older vs younger patients, and others), investigators
frequently perform subgroup analyses, which may provide important information for
patients, clinicians, policymakers, and future research [
[2]
]. However, inappropriate conduct and interpretation of subgroup analyses can result
in misleading reporting of under- or overestimated subgroup effects [
[3]
,
[4]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Thrombosis ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiology of venous thromboembolism.Nat. Rev. Cardiol. 2015; 12: 464-474https://doi.org/10.1038/nrcardio.2015.83
- Statistics in medicine–reporting of subgroup analyses in clinical trials.N. Engl. J. Med. 2007; 357: 2189-2194https://doi.org/10.1056/NEJMsr077003
- Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials.JAMA Intern. Med. 2017; 177: 554-560https://doi.org/10.1001/jamainternmed.2016.9125
- Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.Health Technol. Assess. 2001; 5: 1-56https://doi.org/10.3310/hta5330
- Subgroup analyses in venous thromboembolism trials reporting pharmacological interventions: a systematic review.Thromb. Res. 2022; https://doi.org/10.1016/j.thromres.Q3 2022.09.023
- Credibility of claims of subgroup effects in randomised controlled trials: systematic review.BMJ. 2012; 344e1553https://doi.org/10.1136/bmj.e1553
- Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?.Am. Heart J. 2006; 151: 257-264https://doi.org/10.1016/j.ahj.2005.04.020
- Analyses by sex or gender, race and ethnicity for NIH-defined Phase III Clinical Trials (valid analysis).(Available at) (accessed September 24, 2022)
- NIH policy on sex as a biological variable.(Available at) (accessed September 24, 2022)
- Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation.Lancet. 2005; 365: 176-186https://doi.org/10.1016/S0140-6736(05)17709-5
- Subgroup analyses in randomised controlled trials: cohort study on trial protocols and journal publications.BMJ. 2014; 349g4539https://doi.org/10.1136/bmj.g4539
- New guidelines for statistical reporting in the journal.N. Engl. J. Med. 2019; 381: 285-286https://doi.org/10.1056/NEJMe1906559
Article info
Publication history
Published online: October 17, 2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
